Norton Rose Fulbright Bolsters IP Litigation Team with Two Life Sciences Partners
Event summary
- Norton Rose Fulbright added Sanya Sukduang and Jon Davies as partners in its Washington, DC office, both joining from Cooley.
- The hires strengthen the firm’s life sciences IP disputes team, focusing on pharmaceutical and biotechnology patent litigation.
- Sanya Sukduang brings over 20 years of experience in Hatch-Waxman litigation and biologics disputes.
- Jon Davies holds a PhD in molecular genetics and specializes in pharmaceutical patent litigation, including Hatch-Waxman and BPCIA matters.
The big picture
Norton Rose Fulbright’s strategic investment in its IP disputes team reflects the growing complexity of life sciences patent litigation, driven by regulatory shifts and market demand. The firm’s expansion aligns with broader industry trends, including the rapid advancement of AI, which is expected to enhance IP enforcement and potentially increase litigation. With over 250 IP lawyers globally, Norton Rose Fulbright is positioning itself to meet the evolving needs of clients in the life sciences sector.
What we're watching
- Market Demand
- How the increasing complexity of IP-related challenges will drive further demand for specialized life sciences litigators.
- Regulatory Shifts
- Whether the move of more patent challenges into federal court will sustain the growth of IP litigation.
- AI Impact
- The pace at which AI-enhanced IP enforcement tools will lead to increased patent litigation in the coming years.
Related topics